The abstract is read at the publisher; the summary is JClub's.
Obinutuzumab induced complete remission at week 104 in 26 of 71 adults with primary membranous nephropathy versus 4 of 70 with tacrolimus (37% vs 6%).
- Why it matters: Primary membranous nephropathy needs more effective, well-tolerated therapies, and prior obinutuzumab success in other diseases required evaluation in this kidney condition.
- What they did: In a phase 3 randomized trial, adults received intravenous obinutuzumab or oral tacrolimus, with complete remission at week 104 defined by urine protein-to-creatinine ratio ≤0.3 and stable eGFR.
- The result: The adjusted difference for complete remission at week 104 was 31 percentage points (95% CI, 18 to 44; P<0.001), with higher grade 3+ adverse events (22% vs 19%) and similar infection rates per 100 patient-years.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.